hotspot -WSS

hotspot

author：fashion 2025-09-27 15:35:32 - browse：568

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Peter Marks talks Operation Warp Speed for Rare Diseases

WSS

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Did the public have the right to know Arthur Ashe had AIDS?

Meta looks to target Twitter with a rival app called Threads

RaDonda Vaught case: a double standard for nurses, physicians

Nick Jonas talks about managing diabetes along with his career

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

explore

hotspot

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Bright Health sells Medicare Advantage business to Molina

Doctor appointment wait times are getting worse

Peter Hotez and the public health issue of online harassment

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout LOUD podcast: Merger Mondays, Ozempic panic

Hollywood unions extend contract negotiations for actors

Wellcome Trust names Røttingen as its new CEO

leisure time

Researchers CRISPR chickens in bid to protect them from bird flu

What's changing in Medicare's open enrollment this year?

Make 'food is medicine' a key part of White House nutrition meeting

How doctors and nurses shape Google's AI

Can food be medicine? And other questions about a new push

Nick Jonas talks about managing diabetes along with his career

focus

entertainment

entertainment

hotspot